AdaptVac has entered a manufacturing agreement with ACG Biologics for the manufacture and eventual scaling-up of its candidate for a COVID-19 vaccine.

The partners aim to accelerate the development and manufacture of AdaptVac’s capsid-Virus Like Particle (cVLP) vaccine for use against the coronavirus.

AdaptVac hopes to launch a clinical trial of the vaccine candidate by the end of the year.